BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/24/2019 7:07:40 AM | Browse: 677 | Download: 1071
 |
Received |
|
2019-01-03 02:05 |
|
Peer-Review Started |
|
2019-01-04 05:07 |
|
To Make the First Decision |
|
2019-01-28 06:09 |
|
Return for Revision |
|
2019-02-14 01:43 |
|
Revised |
|
2019-03-12 03:11 |
|
Second Decision |
|
2019-03-18 09:43 |
|
Accepted by Journal Editor-in-Chief |
|
2019-03-18 14:22 |
|
Accepted by Company Editor-in-Chief |
|
2019-03-27 22:48 |
|
Articles in Press |
|
2019-03-27 22:48 |
 |
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-05-23 11:01 |
|
Publish the Manuscript Online |
|
2019-05-24 07:07 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Trishala Meghal, Vishangi Dave, Horace Tang, Vivek Kumar and Yiqing Xu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yiqing Xu, MD, PhD, Associate Professor, Attending Doctor, SUNY Downstate College of Medicine, Division of Hematology and Oncology, Department of Internal Medicine, Maimonides Medical Center, 6300 8th Avenue, Brooklyn, NY 11220, United States. yxu@maimonidesmed.org |
| Key Words |
Ovarian cancer; Intraperitoneal chemotherapy; Community setting; Safety; Tolerability; Outcome |
| Core Tip |
Intraperitoneal chemotherapy has shown survival benefits in the adjuvant setting among the patients with advanced stage ovarian carcinoma undergoing debunking surgery. However, this intraperitoneal route could not be widely adopted due to the number of issues including patients choice and its cumbersome nature. The present study explores its feasibility in a community cancer setting. We have retrospectively analyzed the rates of toxicities and outcome of the patients who received this therapy in our cancer center. We conclude that intraperitoneal chemotherapy can be safely administered in the community cancer setting and improves the overall and progression free survival. |
| Publish Date |
2019-05-24 07:07 |
| Citation |
Meghal T, Dave V, Tang H, Kumar V, Xu Y. Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer. World J Clin Oncol 2019; 10(5): 201-212 |
| URL |
URL: https://www.wjgnet.com/2218-4333/full/v10/i5/201.htm |
| DOI |
DOI: https://dx.doi.org/10.5306/wjco.v10.i5.201 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
